Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin

Published:2018-03-25 Issue:6 Volume:20 Page:1542-1546
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Del Prato Stefano¹^ORCID,Rosenstock Julio²^ORCID,Garcia-Sanchez Ricardo³,Iqbal Nayyar³,Hansen Lars⁴^ORCID,Johnsson Eva⁵,Chen Hungta³,Mathieu Chantal⁶^ORCID

Affiliation:

1. Department of Clinical and Experimental Medicine; University of Pisa; Pisa Italy

2. Dallas Diabetes Research Center at Medical City; Dallas Texas

3. Global Medicines Development; AstraZeneca; Gaithersburg Maryland

4. Global Clinical Research Metabolics; Bristol-Myers Squibb; Princeton New Jersey

5. Global Medicines Development; AstraZeneca; Gothenburg Sweden

6. Clinical and Experimental Endocrinology; University of Leuven; Leuven Belgium

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13258/fullpdf

Reference14 articles.

1. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group;Turner;JAMA,1999

2. Standards of medical care in diabetes-2016;American Diabetes Association;Diabetes Care,2016

3. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetologia,2015

4. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin;Rosenstock;Diabetes Care,2015

5. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes;Mathieu;Diabetes Care,2015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes;Diabetology & Metabolic Syndrome;2023-07-19

2. Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study;Cureus;2023-04-27

3. A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity;Frontiers in Endocrinology;2022-11-11

4. Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus;Frontiers in Medicine;2022-10-14

5. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment;World Journal of Diabetes;2022-02-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3